Global Uterine Fibroids Treatment Market - 2022-2029

Market Overview

Uterine Fibroids Treatment Market size was valued at USD 1,280.20 million in 2021 and is estimated to reach a compound annual growth rate (CAGR) of 9.4% over the forecast period 2022 to 2029.

Uterine fibroids are a woman's uterus's most commonly benign, non-cancerous tumors, often seen during childbearing. Fibroids are only treated if they cause symptoms, and treatment options range from medications to invasive surgery. The uterine fibroids treatment market has significant opportunities to grow. The global uterine fibroids treatment market is primarily driven by an increasing patient pool owing to the increasing female geriatric population, the growing prevalence of hormonal disorders, and changing lifestyles.

Market Dynamics

Major growth drivers of the uterine fibroids treatment market over the globe are an increase in consciousness among individuals about diseases, growth of efficient and new technology, rising government activities over the globe, a surge in occurrence of uterine fibroids, and changed people's lifestyle, and increasing number of women of reproductive age.

The rising incidences of uterine fibroids drive global market growth.

Uterine fibroids are women's most common pelvic tumors, occurring globally, with a prevalence of 21.4%. Uterine leiomyomas are among women's most common yet understudied diseases. The International Federation of Gynecology and Obstetrics 2020 data states that these tumors, commonly known as fibroids, affect women mainly during their reproductive years and are diagnosed in up to 70% of white women and more than 80% of women of African ancestry during their lifetime. This disease has a profound impact on health care delivery and costs worldwide. Though most women with fibroids are asymptomatic, approximately 30% will present with severe symptoms, including abnormal uterine bleeding, anemia, pelvic pain and pressure, back pain, urinary frequency, constipation, or infertility, and will require intervention. Every year in the United States, approximately 6.5 million women seek treatment for fibroids, and nearly 1/3 of employed patients (28%) report missing work days due to fibroid symptoms.

The low awareness of treatment options will hamper the growth of the market.

However, limited attention to fibroids in the community and the medical society means that at-risk women do not have access to the knowledge they need regarding the disease. The 2020 study in the Journal of Women's Health uncovered that only 49% of at-risk women with manifestations suggest fibroids but not a clinical diagnosis of uterine fibroids. Following the onset of their symptoms, most of these women (60%) tried to manage symptoms themselves or waited to see if the symptoms went away (50%). Even when women receive a fibroid diagnosis, their treatment options are limited and affect their fertility. Women can take over-the-counter nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen to alleviate pain associated with uterine fibroids, but these are just momentary fixes for pelvic pain. Some forms of birth control can help alleviate heavy bleeding but don't work for all women and are not an option for women trying to get pregnant.

COVID-19 Impact Analysis

The COVID-19 pandemic had a significant impact on gynecological surgery. The American College of Surgeons has recommended delaying all unnecessary invasive surgery by March 2020. According to a December 2021 research paper titled analysis of response and effects impact of COVID-19 on gynecological surgery in major university hospitals, 1,545 gynecologic cases were done in 2019, compared to 942 cases in 2020, suggesting a 39.0% decline. Negatively impacting the global market.

Segment Analysis

The surgical methods segment is expected to have a greater grasp of the uterine fibroids treatment market during the forecast period (2022-2029).

The surgical methods segment accounts for the largest market share in 2021. Medications can help if the symptoms are mild. However, doctors usually recommend procedures for women whose fibroids cause moderate or severe symptoms, like pain or heavy bleeding. Surgery to treat uterine fibroids can include organ preservation or involve partial or total organ removal. Three approaches (abdominal, laparoscopic, vaginal) or a combination of the three are used for the surgical treatment of uterine fibroids. Several types of surgical procedures are performed for the treatment of uterine fibroids. Dome of them includes endometrial Ablation, MRI Guided Procedures, Hysterectomy, Myomectomy, Uterine Artery Embolization (UAE), and Radiofrequency Ablation, among others. Among these, Hysterectomy accounted for the largest market share in 2021.

Geographical Analysis

North America is expected to dominate the global uterine fibroids treatment market.

North America dominates the market for uterine fibroids treatment and is expected to show a similar trend over the forecast period (2022-2029). Owing to its established healthcare industry, particularly in the U.S. and Canada, increased awareness, and easy accessibility to advanced technologies. The increased patient pool undergoing hormonal disorders and increasing prevalence of uterine cancer is the key growth driving factor for this regional uterine fibroid treatment market. For instance, in the USA, the prevalence of uterine fibroids was 60% at age 35, which increased to more than 80% by 50 years among women.

Moreover, the advent of minimally invasive and effective alternatives to open surgeries, technological advancements, and frequent Treatment Type innovations coupled with an increase in regulatory approvals and favorable reimbursement policies are expected to boost the market's growth in the region.

Competitive Landscape

The uterine fibroids treatment market is a moderately competitive presence of local and global companies. Some of the key players which are contributing to the growth of the market are Boston Scientific Corporation (Minerva Surgical), Cooper Surgical, Inc., Olympus Corporation, Acessa Health (Halt Medical, Inc.), Gynesonics, Conmed Corporation, AbbVie Inc., Medtronic, Karl Storz, Richard Wolf GmbH, LiNA Medical USA, Blue Endo among others. The major players are adopting several growth strategies, such as Treatment Type launches, acquisitions, and collaborations, contributing to the global market growth. For instance, in May 12, 2020, Minerva Surgical, Inc, acquired the following Intrauterine Health Treatment Types from Boston Scientific: the Symphion Tissue Removal System; the Resectr Tissue Resection Device; and the Genesys HTA System.

Boston Scientific Corporation

Overview:

The company was founded in 1979. It has headquarters in the United States. Boston Scientific Corporation develops, manufactures, and markets minimally invasive medical devices. The Company's Treatment Types are used in interventional cardiology, cardiac rhythm management, peripheral interventions, electrophysiology, neurovascular intervention, endoscopy, urology, gynecology, and neuromodulation.

Treatment Type Portfolio:

Symphion Tissue Removal System: The all-in-one Symphion System is designed to transform how you remove uterine tissue. It unites breakthrough fluid management, direct intrauterine pressure monitoring, and bladeless resection to work together perfectly.

The global uterine fibroids treatment report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.